We're sorry, but your current browser configuration is not compatible with this site. Please enable JavaScript or switch to a JavaScript-capable browser. Learn how to enable JavaScript

Pharmacology & Medications

featured

Long-Term Outcome of Primary Immune-Mediated Thrombocytopenia

Why do some patients relapse during or after treatment of IMT? This study looks at risk factors for relapse including use of immunosuppressives other than prednisone and the need for blood transfusion.

Most Popular

Pharmacology & Medications

Top 5 Short Procedure Sedation Scenarios

Peer Reviewed

Complicated Crown Fractures in Dogs

Image Gallery: Adverse Drug Reactions

Peer Reviewed|Web-Exclusive

Quiz: Indicated Versus Contraindicated Corticosteroid Use in Emergency Patients

Peer Reviewed|Web-Exclusive

Capsules

Pharmacology & Medications

Research Note: Akkermansia muciniphila After Antimicrobial Administration

Research Note: Urinary Effects of Allopurinol in Dogs with Leishmaniasis

Research Note: Oral Cobalamin Administration

Research Note: Diazepam in Cats

Therapeutics Research Note: Amitriptyline

Therapeutics Research Note: Adelmidrol

Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

It's Free & Simple

Delivered to Your Inbox

Join the Conversation

Facebook

Twitter

Home

Global Edition

About Us

Employment

Capsules

Brief Media

Create Account

Pharmacology & Medications

Long-Term Outcome of Primary Immune-Mediated Thrombocytopenia

Why do some patients relapse during or after treatment of IMT? This study looks at risk factors for relapse including use of immunosuppressives other than prednisone and the need for blood transfusion.

Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

Subscribe

Newsletter

Facebook

Twitter